home / stock / apvo / apvo news

APVO News and Press, Aptevo Therapeutics Inc. From 11/29/21

Stock Information
Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com
Menu
APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...
APVO - Krystal Biotech, Petros Pharmaceuticals leads healthcare gainers; Fennec Pharmaceuticals, Allied Healthcare Products among major losers

Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...
APVO - ESPR, LOV and BFRA among mid-day movers

Gainers: Biofrontera (NASDAQ:BFRI) +154%. Longeveron (NASDAQ:LGVN) +79%. Ocuphire Pharma (NASDAQ:OCUP) +36%. Society Pass (NASDAQ:SOPA) +24%. Biofrontera (NASDAQ:BFRA) +23%. Better Therapeutics (NASDAQ:BTTX) +20%. Applied UV (NASDAQ:AUVI) +19%. Standard Lithium (NYSE:SLI) +19%. Blue Star Food...

APVO - Biofrontera, Longeveron leads healthcare gainers; Vallon Pharmaceuticals, Pasithea Therapeutics among major losers

Gainers: Biofrontera (NASDAQ:BFRI) +109%, Longeveron (NASDAQ:LGVN) +87%, Ocuphire Pharma (NASDAQ:OCUP) +41%, Better Therapeutics (NASDAQ:BTTX) +24%, Reviva Pharmaceuticals (NASDAQ:RVPH) +12%. Losers: Vallon Pharmaceuticals (NASDAQ:VLON) -34%, Pasithea Therap...

APVO - XL, CLMT and AYTU among pre market gainers

Pasithea Therapeutics (NASDAQ:KTTA) +172% adds Esketamine nasal spray to its clinic offerings in the U.K. Petros Pharmaceuticals (NASDAQ:PTPI) +99%. iSpecimen ISPC +99% is set to extend rally after contract win for COVID-19 research Qualigen Therapeutics (NASDAQ:QLGN) +72%. Aad...
APVO - Aptevo gains nearly double after APVO436 + chemotherapy resulted in complete remission in AML

Aptevo Therapeutics (NASDAQ:APVO) soars 99.4% premarket after announcing a clinical update for its Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia (AML). A high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO43...

APVO - Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...

APVO - FEMY, APVO and LTRY among mid-day movers

Gainers: Longeveron (NASDAQ:LGVN) +137%. Virtuoso (NASDAQ:VOSOU) +89%. Dicerna (NASDAQ:DRNA) +79%. ClearSign (NASDAQ:CLIR) +33%. Alpine (NASDAQ:ALPP) +22%. Macy's (NYSE:M) +21%. Enthusiast Gaming Holdings (NASDAQ:EGLX) +20%. BJ's (NYSE:BJ) +19%. Jowell Global (NASDAQ:JWEL) +17%. Yatsen Holdin...
APVO - Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting

SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...

APVO - Aptevo Therapeutics EPS beats by $0.03, misses on revenue

Aptevo Therapeutics (NASDAQ:APVO): Q3 GAAP EPS of -$1.45 beats by $0.03. Revenue of $3.1M (+112.3% Y/Y) misses by $0.55M. Press Release For further details see: Aptevo Therapeutics EPS beats by $0.03, misses on revenue

APVO - Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...
Previous 10 Next 10